Literature DB >> 25256065

Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.

Roberto Adamo1, Alberto Nilo, Carole Harfouche, Barbara Brogioni, Simone Pecetta, Giulia Brogioni, Evita Balducci, Vittoria Pinto, Sara Filippini, Elena Mori, Marta Tontini, Maria Rosaria Romano, Paolo Costantino, Francesco Berti.   

Abstract

Multicomponent constructs, obtained by coupling different glycans to the carrier protein, have been proposed as a way to co-deliver multiple surface carbohydrates targeting different strains of one pathogen and reduce the number of biomolecules in the formulation of multivalent vaccines. To assess the feasibility of this approach for anti-microbial vaccines and investigate the potential immunodominance of one carbohydrate antigen over the others in these constructs, we designed a bivalent unimolecular vaccine against serogroup A (MenA) and C (MenC) meningococci, with the two different oligomers conjugated to same molecule of carrier protein (CRM197). The immune response elicited in mice by the bivalent MenAC construct was compared with the ones induced by the monovalent MenA and MenC vaccines and their combinations. After the second dose, the bivalent construct induced good levels of anti-MenA and anti-MenC antibodies with respect to the controls. However, the murine sera from the MenAC construct exhibited good anti-MenC bactericidal activity, and very low anti-MenA functionality when compared to the monovalent controls. This result was explained with the diverse relative avidities against MenA and MenC polysaccharides, which were measured in the generated sera. The immunodominant effect of the MenC antigen was fully overcome following the third immunization, when sera endowed with higher avidity and excellent bactericidal activity against both MenA and MenC expressing strains were elicited. Construction of multicomponent glycoconjugate vaccines against microbial pathogens is a feasible approach, but particular attention should be devoted to study and overcome possible occurrence of immune interference among the carbohydrates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25256065     DOI: 10.1007/s10719-014-9559-1

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  41 in total

1.  Increase in admissions for Neisseria meningitidis infection in Australia.

Authors:  D A Clements; G L Gilbert
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

2.  Defined conjugation of glycans to the lysines of CRM197 guided by their reactivity mapping.

Authors:  Stefano Crotti; Huili Zhai; Jing Zhou; Martin Allan; Daniela Proietti; Werner Pansegrau; Qi-Ying Hu; Francesco Berti; Roberto Adamo
Journal:  Chembiochem       Date:  2014-03-11       Impact factor: 3.164

3.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

4.  The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies.

Authors:  Marzia Monica Giuliani; Laura Santini; Brunella Brunelli; Alessia Biolchi; Beatrice Aricò; Federica Di Marcello; Elena Cartocci; Maurizio Comanducci; Vega Masignani; Luisa Lozzi; Silvana Savino; Maria Scarselli; Rino Rappuoli; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 5.  How bacterial carbohydrates influence the adaptive immune system.

Authors:  Fikri Y Avci; Dennis L Kasper
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

6.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.

Authors:  Aileen F G Bongat; Rina Saksena; Roberto Adamo; Yukari Fujimoto; Zenyu Shiokawa; Dwight C Peterson; Koichi Fukase; Willie F Vann; Pavol Kovác
Journal:  Glycoconj J       Date:  2009-09-16       Impact factor: 2.916

Review 8.  Immunotherapy for cancer: synthetic carbohydrate-based vaccines.

Authors:  Therese Buskas; Pamela Thompson; Geert-Jan Boons
Journal:  Chem Commun (Camb)       Date:  2009-07-22       Impact factor: 6.222

9.  Synthetically defined glycoprotein vaccines: current status and future directions.

Authors:  Roberto Adamo; Alberto Nilo; Bastien Castagner; Omar Boutureira; Francesco Berti; Gonçalo J L Bernardes
Journal:  Chem Sci       Date:  2013-05-16       Impact factor: 9.825

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  5 in total

Review 1.  Carbohydrate based meningococcal vaccines: past and present overview.

Authors:  Francesco Berti; Maria Rosaria Romano; Francesca Micoli; Roberto Adamo
Journal:  Glycoconj J       Date:  2021-04-27       Impact factor: 2.916

2.  Simulating Immune Interference on the Effect of a Bivalent Glycoconjugate Vaccine against Haemophilus influenzae Serotypes "a" and "b".

Authors:  Angjelina Konini; Mingsong Kang; Seyed M Moghadas
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-03-02       Impact factor: 2.471

3.  Multicomponent polysaccharide-protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates.

Authors:  Yanira Méndez; Janoi Chang; Ana R Humpierre; Abel Zanuy; Raine Garrido; Aldrin V Vasco; Jessy Pedroso; Darielys Santana; Laura M Rodríguez; Dagmar García-Rivera; Yury Valdés; Vicente Vérez-Bencomo; Daniel G Rivera
Journal:  Chem Sci       Date:  2018-01-19       Impact factor: 9.825

4.  A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A.

Authors:  Jacopo Enotarpi; Marta Tontini; Cristiana Balocchi; Daan van der Es; Ludovic Auberger; Evita Balducci; Filippo Carboni; Daniela Proietti; Daniele Casini; Dmitri V Filippov; Hermen S Overkleeft; Gijsbert A van der Marel; Cinzia Colombo; Maria Rosaria Romano; Francesco Berti; Paolo Costantino; Jeroen D C Codeé; Luigi Lay; Roberto Adamo
Journal:  Nat Commun       Date:  2020-09-07       Impact factor: 14.919

5.  Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM197 as carrier protein.

Authors:  G Stefanetti; M Allan; A Usera; F Micoli
Journal:  Glycoconj J       Date:  2020-06-13       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.